Bill > SB269

This bill amends the Newborn Child Testing Act to expand the state's Newborn Child Screening and Follow-up Program by adding Duchenne muscular dystrophy (DMD) to the list of diseases for which newborns are screened. Duchenne muscular dystrophy is a rare, progressive genetic disorder characterized by muscle weakness and degeneration that primarily affects male children. The bill requires the state department of health, with approval from the Newborn Screening and Follow-up Technical Advisory Board, to include DMD screening tests as part of its existing newborn screening program. The purpose of this screening is to help healthcare providers identify potential cases early, which could allow for earlier intervention, treatment, or services to mitigate the potential intellectual or physical disabilities associated with the condition. The bill will take effect 60 days after its enactment, ensuring that the new screening protocol can be implemented in a timely manner.

Health and Social Services

https://www.legis.state.pa.us/cfdocs/billinfo/bill_history.cfm?syear=2025&sind=0&body=S&type=B&bn=269